查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1476380

到 2030 年急性癲癇群聚市場預測：按產品類型、給藥途徑、分銷管道、最終用戶和地區進行的全球分析

Acute Repetitive Seizures Market Forecasts to 2030 - Global Analysis By Product (Diastat Rectal Gel, AZ-002, NRL-1, USL-261 and Other Products), Drug Type, Route of Administration, Distribution Channel, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，2023 年全球急性叢集性癲癇市場規模為 29 億美元，預計到 2030 年將達到 76 億美元，預測期內複合年成長率為 14.4%。

急性重複性癲癇發作 (ARS) 是在相對較短的時間內（通常在 24 小時內）連續發生的癲癇發作。這些發作的特徵是反覆發作，儘管採取了正常的癲癇發作控制措施（例如遵守用藥），也可能發生。這些癲癇發作可能發生在多種類型的癲癇中，如果不能迅速控制，可能會危及生命，因此需要緊急醫療護理來控制癲癇發作並防止進一步癲癇發作。

據世界衛生組織 (WHO) 稱，癲癇是一種神經系統疾病，影響全球約 5,000 萬人。

癲癇盛行率上升

市場對癲癇盛行率不斷上升感到擔憂。這一趨勢表明越來越多的人口受到反覆出現和不可預測的攻擊的影響，因此需要先進的治療性介入和管理策略。癲癇患者數量的迅速增加凸顯了對創新治療、個人化護理計劃和加強宣傳宣傳活動的迫切需要，以應對這種神經系統疾病患者面臨的複雜挑戰。

缺乏意識

儘管癲癇治療取得了重大進展，但市場認知度仍然很低。許多人，包括醫療保健提供者和公眾，可能不完全了解患者面臨的挑戰或可用的治療方案。這種意識差距阻礙了及時診斷、適當的管理和獲得創新治療方法，並需要有針對性的教育和宣傳工作來改善管理結果。

新藥開發

目前正在研究新的作用機制，例如針對參與癲癇發作的特定離子通道和神經傳導物質系統。此外，鼻腔和經皮製劑等藥物傳遞方法的進步旨在提高患者的依從性和治療結果。這些努力意味著採取積極主動的方法來最佳化癲癇患者的治療方案。

治療費用高

急性復發性癲癇（ARS）市場的高治療成本是一個重大問題，並且常常超出患者和醫療保健系統的財務能力。治療費用包括診斷測試、藥物、住院和持續監測，這是一筆巨大的經濟負擔。這種成本障礙可能會限制獲得基本治療方法的機會，並影響患者的治療結果和生活品質。

COVID-19 的影響：

COVID-19 大流行對急性復發性癲癇發作 (ARS) 市場產生了重大影響。獲得醫療服務的機會受到干擾，導致許多患者的診斷和治療延誤。臨床試驗和研究計畫也面臨挫折，影響了新治療方法的發展。然而，遠端醫療和遠端監控的普及提供了患者管理的替代方法。

巴比妥類藥物預計在預測期內成為最大的藥物市場

巴比妥類藥物預計在預測期內將是最大的。巴比妥酸鹽藥長期以來一直是一種選擇，但由於安全問題和更有效的新藥物的開發，其使用已經減少。在市場上，巴比妥酸鹽藥在其他治療方法無效或禁忌的特定情況下發揮特殊作用。儘管用途有限，但Phenobarbital類巴比妥酸鹽藥對於某些患者可能是可行的，特別是在資源有限的情況下或根據個別患者的需求進行客製化時，它仍然是一種選擇。

預計居家照護產業在預測期內複合年成長率最高。

預計居家照護環境領域在預測期內將經歷最高的複合年成長率。家庭護理環境包括各種服務，例如監控設備、看護者培訓和緊急應變計劃。隨著遠端醫療和遠端監控技術的進步，居家照護環境變得越來越複雜，提高了個人管理急性發作群的便利性和舒適性，同時實現了即時干預並改善了患者的治療效果。

佔比最大的地區：

由於意識提高、診斷技術改進和患者數量增加等因素，預計北美在預測期內將佔據最大的市場佔有率。該市場的主要參與者專注於開發先進的治療方法和藥物，以滿足未滿足的醫療需求。此外，政府措施和醫療改革在提高輔助生殖服務治療的可及性方面發揮著關鍵作用，為該地區的市場擴張帶來了光明的前景。

複合年成長率最高的地區：

預計亞太地區在預測期內複合年成長率最高。 ARS 是一種影響該地區大量人口的嚴重疾病。認知宣傳活動和改進的診斷方法正在增加我們對這種疾病的了解，並增加對有效治療方法的需求。製藥公司、研究機構和醫療保健提供者之間的競爭正在推動 ARS 治療的創新和降低價格。

免費客製化服務

訂閱此報告的客戶可以存取以下免費自訂選項之一：

  • 公司簡介
    • 其他市場參與者的綜合分析（最多 3 家公司）
    • 主要企業SWOT分析（最多3家企業）
  • 區域分割
    • 根據客戶興趣對主要國家的市場估計、預測和複合年成長率（註：基於可行性檢查）
  • 競爭基準化分析
    • 根據產品系列、地理分佈和策略聯盟對主要企業基準化分析

目錄

第1章執行摘要

第2章 前言

  • 概述
  • 相關利益者
  • 調查範圍
  • 調查方法
    • 資料探勘
    • 資料分析
    • 資料檢驗
    • 研究途徑
  • 研究資訊來源
    • 主要研究資訊來源
    • 二次研究資訊來源
    • 先決條件

第3章市場趨勢分析

  • 促進因素
  • 抑制因素
  • 機會
  • 威脅
  • 產品分析
  • 最終用戶分析
  • 新興市場
  • COVID-19 的影響

第4章波特五力分析

  • 供應商的議價能力
  • 買方議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭公司之間的敵對關係

第5章全球急性叢集性癲癇市場：依產品

  • Diastat直腸凝膠
  • AZ-002
  • NRL-1
  • USL-261
  • 其他產品

第6章全球急性叢集性癲癇市場：依藥物類型

  • 苯二氮平類
  • 巴比妥酸
  • 抗癲癇藥 (AED)
  • 其他藥物種類

第7章全球急性叢集性癲癇市場：依途徑

  • 鼻腔
  • 口服
  • 靜脈

第8章全球急性叢集性癲癇市場：依通路分類

  • 專科診所
  • 零售藥房
  • 醫院
  • 網路藥房

第9章全球急性叢集性癲癇市場：依最終使用者分類

  • 居家照護環境
  • 診所
  • 其他最終用戶

第10章全球急性叢集性癲癇市場：按地區

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地區
  • 中東/非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他中東和非洲

第11章 主要進展

  • 合約、夥伴關係、協作和合資企業
  • 收購和合併
  • 新產品發布
  • 業務擴展
  • 其他關鍵策略

第12章 公司概況

  • Bausch Health Companies Inc.
  • UCB Pharma
  • Eisai Co., Ltd.
  • SK Biopharmaceuticals Co., Ltd.
  • Valeant Pharmaceuticals North America LLC
  • Sunovion Pharmaceuticals
  • GW Pharmaceuticals
  • Pfizer Inc.
  • Marinus Pharmaceuticals
  • Neurelis, Inc.
  • Sanofi
  • Novartis AG
  • Alexza
  • Veriton Pharma
Product Code: SMRC25926

According to Stratistics MRC, the Global Acute Repetitive Seizures Market is accounted for $2.9 billion in 2023 and is expected to reach $7.6 billion by 2030 growing at a CAGR of 14.4% during the forecast period. Acute Repetitive Seizures (ARS) is a series of epileptic seizures that occur in rapid succession within a relatively short period, typically within 24 hours. These seizures are characterized by their repetitive nature and can occur despite the person's normal seizure control measures, such as medication adherence. They can occur in various types of epilepsy and may require urgent medical attention to manage and prevent further seizures, as they can be dangerous and potentially life-threatening if not controlled promptly.

According to World Health Organization (WHO), epilepsy is a neurological condition affecting about 50 million people worldwide.

Market Dynamics:

Driver:

Rising prevalence of epilepsy

The market is witnessing a concerning rise in epilepsy prevalence. This trend indicates a growing population affected by recurrent and unpredictable seizures, necessitating advanced therapeutic interventions and management strategies. The surge in epilepsy cases within the sector underscores the pressing need for innovative treatments, personalized care plans, and heightened awareness campaigns to address the complex challenges faced by individuals grappling with this neurological disorder.

Restraint:

Lack of awareness

Despite significant advancements in epilepsy treatment, there remains a notable lack of awareness in the market. Many individuals, including healthcare providers and the general public, may not fully grasp the challenges faced by patients or the available therapeutic options. This gap in awareness hinders timely diagnosis, appropriate management, and access to innovative treatments, highlighting the need for targeted education and advocacy efforts to improve outcomes in management.

Opportunity:

Development of new drugs

Research is geared towards novel mechanisms of action, such as targeting specific ion channels or neurotransmitter systems implicated in seizure generation. Additionally, advancements in drug delivery methods, like intranasal or transdermal formulations, aim to improve patient compliance and treatment outcomes. These efforts signify a proactive approach to optimizing therapeutic options for individuals with the market.

Threat:

High cost of treatment

The high cost of treatment in the Acute Repetitive Seizures (ARS) market is a significant concern, often exceeding the financial capacities of patients and healthcare systems alike. The expenses encompass diagnostic tests, medications, hospitalizations, and ongoing monitoring, creating a considerable financial burden. This cost barrier can limit access to essential therapies, impacting patient outcomes and quality of life.

Covid-19 Impact:

The COVID-19 pandemic significantly impacted the Acute Repetitive Seizures (ARS) market. Access to healthcare services was disrupted, leading to delayed diagnosis and treatment for many patients. Clinical trials and research initiatives also faced setbacks, affecting the development of new therapies. However, telemedicine and remote monitoring gained traction, offering alternative ways to manage patients.

The barbiturates segment is expected to be the largest during the forecast period

The barbiturates segment is expected to be the largest during the forecast period. Barbiturates have been a longstanding option, but their use has declined due to safety concerns and the development of newer, more effective medications. In the market, they occupy a niche role for specific cases where other treatments have failed or are contraindicated. Despite their limited use, barbiturates like phenobarbital remain a viable option for certain patients, particularly in resource-limited settings or when tailored to individual patient needs.

The home care settings segment is expected to have the highest CAGR during the forecast period

The home care settings segment is expected to have the highest CAGR during the forecast period. These settings encompass a range of services, including monitoring equipment, caregiver training, and emergency response plans. With advancements in telemedicine and remote monitoring technologies, home care settings have become increasingly sophisticated, enabling real-time interventions and improving patient outcomes while enhancing convenience and comfort for individuals managing acute repetitive seizures.

Region with largest share:

North America is projected to hold the largest market share during the forecast period driven by factors such as increasing awareness, improved diagnostic technologies, and a growing patient population. Key players in this market focus on developing advanced therapies and medications to address unmet medical needs. Additionally, government initiatives and healthcare reforms are playing a crucial role in enhancing access to ARS treatments, leading to a promising outlook for market expansion in the region.

Region with highest CAGR:

Asia Pacific is projected to hold the highest CAGR over the forecast period. It is a serious condition that affects a significant number of people in the region. Awareness campaigns and improved diagnosis have contributed to a better understanding of the condition, leading to increased demand for effective treatments. Competition among pharmaceutical companies, research institutions, and healthcare providers drives innovation and affordability in ARS treatments.

Key players in the market

Some of the key players in Acute Repetitive Seizures market include Bausch Health Companies Inc., UCB Pharma, Eisai Co., Ltd., SK Biopharmaceuticals Co., Ltd., Valeant Pharmaceuticals North America LLC, Sunovion Pharmaceuticals, GW Pharmaceuticals, Pfizer Inc., Marinus Pharmaceuticals, Neurelis, Inc., Sanofi, Novartis AG, Alexza and Veriton Pharma.

Key Developments:

In May 2019, UCB declared that the U.S. FDA has permitted a New Drug Application for the company's latest anti-epileptic drug (AED) NAYZILAM(R) nasal spray CIV. It is a benzodiazepine designated for the stereotypic incidents of recurrent seizure activity and acute treatment of intermittent that are different from a patient's normal seizure form in person with epilepsy 12 years and older1.

In September 2018, Neurelis, Inc., a pharmaceutical firm based in San Diego, California, submitted a New Drug Application (NDA) to the FDA for VALTOCO as a treatment for epilepsy patients with acute repeated seizures.

Products Covered:

  • Diastat Rectal Gel
  • AZ-002
  • NRL-1
  • USL-261
  • Other Products

Drug Types Covered:

  • Benzodiazepines
  • Barbiturates
  • Antiepileptic Drugs (AEDs)
  • Other Drug Types

Route of Administrations Covered:

  • Intranasal Formulations
  • Oral
  • Intravenous

Distribution Channels Covered:

  • Specialty Clinics
  • Retail Pharmacies
  • Hospitals
  • Online Pharmacies

End Users Covered:

  • Home Care Settings
  • Clinics
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 End User Analysis
  • 3.8 Emerging Markets
  • 3.9 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Acute Repetitive Seizures Market, By Product

  • 5.1 Introduction
  • 5.2 Diastat Rectal Gel
  • 5.3 AZ-002
  • 5.4 NRL-1
  • 5.5 USL-261
  • 5.6 Other Products

6 Global Acute Repetitive Seizures Market, By Drug Type

  • 6.1 Introduction
  • 6.2 Benzodiazepines
  • 6.3 Barbiturates
  • 6.4 Antiepileptic Drugs (AEDs)
  • 6.5 Other Drug Types

7 Global Acute Repetitive Seizures Market, By Route of Administration

  • 7.1 Introduction
  • 7.2 Intranasal Formulations
  • 7.3 Oral
  • 7.4 Intravenous

8 Global Acute Repetitive Seizures Market, By Distribution Channel

  • 8.1 Introduction
  • 8.2 Specialty Clinics
  • 8.3 Retail Pharmacies
  • 8.4 Hospitals
  • 8.5 Online Pharmacies

9 Global Acute Repetitive Seizures Market, By End User

  • 9.1 Introduction
  • 9.2 Home Care Settings
  • 9.3 Clinics
  • 9.4 Other End Users

10 Global Acute Repetitive Seizures Market, By Geography

  • 10.1 Introduction
  • 10.2 North America
    • 10.2.1 US
    • 10.2.2 Canada
    • 10.2.3 Mexico
  • 10.3 Europe
    • 10.3.1 Germany
    • 10.3.2 UK
    • 10.3.3 Italy
    • 10.3.4 France
    • 10.3.5 Spain
    • 10.3.6 Rest of Europe
  • 10.4 Asia Pacific
    • 10.4.1 Japan
    • 10.4.2 China
    • 10.4.3 India
    • 10.4.4 Australia
    • 10.4.5 New Zealand
    • 10.4.6 South Korea
    • 10.4.7 Rest of Asia Pacific
  • 10.5 South America
    • 10.5.1 Argentina
    • 10.5.2 Brazil
    • 10.5.3 Chile
    • 10.5.4 Rest of South America
  • 10.6 Middle East & Africa
    • 10.6.1 Saudi Arabia
    • 10.6.2 UAE
    • 10.6.3 Qatar
    • 10.6.4 South Africa
    • 10.6.5 Rest of Middle East & Africa

11 Key Developments

  • 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 11.2 Acquisitions & Mergers
  • 11.3 New Product Launch
  • 11.4 Expansions
  • 11.5 Other Key Strategies

12 Company Profiling

  • 12.1 Bausch Health Companies Inc.
  • 12.2 UCB Pharma
  • 12.3 Eisai Co., Ltd.
  • 12.4 SK Biopharmaceuticals Co., Ltd.
  • 12.5 Valeant Pharmaceuticals North America LLC
  • 12.6 Sunovion Pharmaceuticals
  • 12.7 GW Pharmaceuticals
  • 12.8 Pfizer Inc.
  • 12.9 Marinus Pharmaceuticals
  • 12.10 Neurelis, Inc.
  • 12.11 Sanofi
  • 12.12 Novartis AG
  • 12.13 Alexza
  • 12.14 Veriton Pharma

List of Tables

  • Table 1 Global Acute Repetitive Seizures Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Acute Repetitive Seizures Market Outlook, By Product (2021-2030) ($MN)
  • Table 3 Global Acute Repetitive Seizures Market Outlook, By Diastat Rectal Gel (2021-2030) ($MN)
  • Table 4 Global Acute Repetitive Seizures Market Outlook, By AZ-002 (2021-2030) ($MN)
  • Table 5 Global Acute Repetitive Seizures Market Outlook, By NRL-1 (2021-2030) ($MN)
  • Table 6 Global Acute Repetitive Seizures Market Outlook, By USL-261 (2021-2030) ($MN)
  • Table 7 Global Acute Repetitive Seizures Market Outlook, By Other Products (2021-2030) ($MN)
  • Table 8 Global Acute Repetitive Seizures Market Outlook, By Drug Type (2021-2030) ($MN)
  • Table 9 Global Acute Repetitive Seizures Market Outlook, By Benzodiazepines (2021-2030) ($MN)
  • Table 10 Global Acute Repetitive Seizures Market Outlook, By Barbiturates (2021-2030) ($MN)
  • Table 11 Global Acute Repetitive Seizures Market Outlook, By Antiepileptic Drugs (AEDs) (2021-2030) ($MN)
  • Table 12 Global Acute Repetitive Seizures Market Outlook, By Other Drug Types (2021-2030) ($MN)
  • Table 13 Global Acute Repetitive Seizures Market Outlook, By Route of Administration (2021-2030) ($MN)
  • Table 14 Global Acute Repetitive Seizures Market Outlook, By Intranasal Formulations (2021-2030) ($MN)
  • Table 15 Global Acute Repetitive Seizures Market Outlook, By Oral (2021-2030) ($MN)
  • Table 16 Global Acute Repetitive Seizures Market Outlook, By Intravenous (2021-2030) ($MN)
  • Table 17 Global Acute Repetitive Seizures Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 18 Global Acute Repetitive Seizures Market Outlook, By Specialty Clinics (2021-2030) ($MN)
  • Table 19 Global Acute Repetitive Seizures Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
  • Table 20 Global Acute Repetitive Seizures Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 21 Global Acute Repetitive Seizures Market Outlook, By Online Pharmacies (2021-2030) ($MN)
  • Table 22 Global Acute Repetitive Seizures Market Outlook, By End User (2021-2030) ($MN)
  • Table 23 Global Acute Repetitive Seizures Market Outlook, By Home Care Settings (2021-2030) ($MN)
  • Table 24 Global Acute Repetitive Seizures Market Outlook, By Clinics (2021-2030) ($MN)
  • Table 25 Global Acute Repetitive Seizures Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 26 North America Acute Repetitive Seizures Market Outlook, By Country (2021-2030) ($MN)
  • Table 27 North America Acute Repetitive Seizures Market Outlook, By Product (2021-2030) ($MN)
  • Table 28 North America Acute Repetitive Seizures Market Outlook, By Diastat Rectal Gel (2021-2030) ($MN)
  • Table 29 North America Acute Repetitive Seizures Market Outlook, By AZ-002 (2021-2030) ($MN)
  • Table 30 North America Acute Repetitive Seizures Market Outlook, By NRL-1 (2021-2030) ($MN)
  • Table 31 North America Acute Repetitive Seizures Market Outlook, By USL-261 (2021-2030) ($MN)
  • Table 32 North America Acute Repetitive Seizures Market Outlook, By Other Products (2021-2030) ($MN)
  • Table 33 North America Acute Repetitive Seizures Market Outlook, By Drug Type (2021-2030) ($MN)
  • Table 34 North America Acute Repetitive Seizures Market Outlook, By Benzodiazepines (2021-2030) ($MN)
  • Table 35 North America Acute Repetitive Seizures Market Outlook, By Barbiturates (2021-2030) ($MN)
  • Table 36 North America Acute Repetitive Seizures Market Outlook, By Antiepileptic Drugs (AEDs) (2021-2030) ($MN)
  • Table 37 North America Acute Repetitive Seizures Market Outlook, By Other Drug Types (2021-2030) ($MN)
  • Table 38 North America Acute Repetitive Seizures Market Outlook, By Route of Administration (2021-2030) ($MN)
  • Table 39 North America Acute Repetitive Seizures Market Outlook, By Intranasal Formulations (2021-2030) ($MN)
  • Table 40 North America Acute Repetitive Seizures Market Outlook, By Oral (2021-2030) ($MN)
  • Table 41 North America Acute Repetitive Seizures Market Outlook, By Intravenous (2021-2030) ($MN)
  • Table 42 North America Acute Repetitive Seizures Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 43 North America Acute Repetitive Seizures Market Outlook, By Specialty Clinics (2021-2030) ($MN)
  • Table 44 North America Acute Repetitive Seizures Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
  • Table 45 North America Acute Repetitive Seizures Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 46 North America Acute Repetitive Seizures Market Outlook, By Online Pharmacies (2021-2030) ($MN)
  • Table 47 North America Acute Repetitive Seizures Market Outlook, By End User (2021-2030) ($MN)
  • Table 48 North America Acute Repetitive Seizures Market Outlook, By Home Care Settings (2021-2030) ($MN)
  • Table 49 North America Acute Repetitive Seizures Market Outlook, By Clinics (2021-2030) ($MN)
  • Table 50 North America Acute Repetitive Seizures Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 51 Europe Acute Repetitive Seizures Market Outlook, By Country (2021-2030) ($MN)
  • Table 52 Europe Acute Repetitive Seizures Market Outlook, By Product (2021-2030) ($MN)
  • Table 53 Europe Acute Repetitive Seizures Market Outlook, By Diastat Rectal Gel (2021-2030) ($MN)
  • Table 54 Europe Acute Repetitive Seizures Market Outlook, By AZ-002 (2021-2030) ($MN)
  • Table 55 Europe Acute Repetitive Seizures Market Outlook, By NRL-1 (2021-2030) ($MN)
  • Table 56 Europe Acute Repetitive Seizures Market Outlook, By USL-261 (2021-2030) ($MN)
  • Table 57 Europe Acute Repetitive Seizures Market Outlook, By Other Products (2021-2030) ($MN)
  • Table 58 Europe Acute Repetitive Seizures Market Outlook, By Drug Type (2021-2030) ($MN)
  • Table 59 Europe Acute Repetitive Seizures Market Outlook, By Benzodiazepines (2021-2030) ($MN)
  • Table 60 Europe Acute Repetitive Seizures Market Outlook, By Barbiturates (2021-2030) ($MN)
  • Table 61 Europe Acute Repetitive Seizures Market Outlook, By Antiepileptic Drugs (AEDs) (2021-2030) ($MN)
  • Table 62 Europe Acute Repetitive Seizures Market Outlook, By Other Drug Types (2021-2030) ($MN)
  • Table 63 Europe Acute Repetitive Seizures Market Outlook, By Route of Administration (2021-2030) ($MN)
  • Table 64 Europe Acute Repetitive Seizures Market Outlook, By Intranasal Formulations (2021-2030) ($MN)
  • Table 65 Europe Acute Repetitive Seizures Market Outlook, By Oral (2021-2030) ($MN)
  • Table 66 Europe Acute Repetitive Seizures Market Outlook, By Intravenous (2021-2030) ($MN)
  • Table 67 Europe Acute Repetitive Seizures Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 68 Europe Acute Repetitive Seizures Market Outlook, By Specialty Clinics (2021-2030) ($MN)
  • Table 69 Europe Acute Repetitive Seizures Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
  • Table 70 Europe Acute Repetitive Seizures Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 71 Europe Acute Repetitive Seizures Market Outlook, By Online Pharmacies (2021-2030) ($MN)
  • Table 72 Europe Acute Repetitive Seizures Market Outlook, By End User (2021-2030) ($MN)
  • Table 73 Europe Acute Repetitive Seizures Market Outlook, By Home Care Settings (2021-2030) ($MN)
  • Table 74 Europe Acute Repetitive Seizures Market Outlook, By Clinics (2021-2030) ($MN)
  • Table 75 Europe Acute Repetitive Seizures Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 76 Asia Pacific Acute Repetitive Seizures Market Outlook, By Country (2021-2030) ($MN)
  • Table 77 Asia Pacific Acute Repetitive Seizures Market Outlook, By Product (2021-2030) ($MN)
  • Table 78 Asia Pacific Acute Repetitive Seizures Market Outlook, By Diastat Rectal Gel (2021-2030) ($MN)
  • Table 79 Asia Pacific Acute Repetitive Seizures Market Outlook, By AZ-002 (2021-2030) ($MN)
  • Table 80 Asia Pacific Acute Repetitive Seizures Market Outlook, By NRL-1 (2021-2030) ($MN)
  • Table 81 Asia Pacific Acute Repetitive Seizures Market Outlook, By USL-261 (2021-2030) ($MN)
  • Table 82 Asia Pacific Acute Repetitive Seizures Market Outlook, By Other Products (2021-2030) ($MN)
  • Table 83 Asia Pacific Acute Repetitive Seizures Market Outlook, By Drug Type (2021-2030) ($MN)
  • Table 84 Asia Pacific Acute Repetitive Seizures Market Outlook, By Benzodiazepines (2021-2030) ($MN)
  • Table 85 Asia Pacific Acute Repetitive Seizures Market Outlook, By Barbiturates (2021-2030) ($MN)
  • Table 86 Asia Pacific Acute Repetitive Seizures Market Outlook, By Antiepileptic Drugs (AEDs) (2021-2030) ($MN)
  • Table 87 Asia Pacific Acute Repetitive Seizures Market Outlook, By Other Drug Types (2021-2030) ($MN)
  • Table 88 Asia Pacific Acute Repetitive Seizures Market Outlook, By Route of Administration (2021-2030) ($MN)
  • Table 89 Asia Pacific Acute Repetitive Seizures Market Outlook, By Intranasal Formulations (2021-2030) ($MN)
  • Table 90 Asia Pacific Acute Repetitive Seizures Market Outlook, By Oral (2021-2030) ($MN)
  • Table 91 Asia Pacific Acute Repetitive Seizures Market Outlook, By Intravenous (2021-2030) ($MN)
  • Table 92 Asia Pacific Acute Repetitive Seizures Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 93 Asia Pacific Acute Repetitive Seizures Market Outlook, By Specialty Clinics (2021-2030) ($MN)
  • Table 94 Asia Pacific Acute Repetitive Seizures Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
  • Table 95 Asia Pacific Acute Repetitive Seizures Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 96 Asia Pacific Acute Repetitive Seizures Market Outlook, By Online Pharmacies (2021-2030) ($MN)
  • Table 97 Asia Pacific Acute Repetitive Seizures Market Outlook, By End User (2021-2030) ($MN)
  • Table 98 Asia Pacific Acute Repetitive Seizures Market Outlook, By Home Care Settings (2021-2030) ($MN)
  • Table 99 Asia Pacific Acute Repetitive Seizures Market Outlook, By Clinics (2021-2030) ($MN)
  • Table 100 Asia Pacific Acute Repetitive Seizures Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 101 South America Acute Repetitive Seizures Market Outlook, By Country (2021-2030) ($MN)
  • Table 102 South America Acute Repetitive Seizures Market Outlook, By Product (2021-2030) ($MN)
  • Table 103 South America Acute Repetitive Seizures Market Outlook, By Diastat Rectal Gel (2021-2030) ($MN)
  • Table 104 South America Acute Repetitive Seizures Market Outlook, By AZ-002 (2021-2030) ($MN)
  • Table 105 South America Acute Repetitive Seizures Market Outlook, By NRL-1 (2021-2030) ($MN)
  • Table 106 South America Acute Repetitive Seizures Market Outlook, By USL-261 (2021-2030) ($MN)
  • Table 107 South America Acute Repetitive Seizures Market Outlook, By Other Products (2021-2030) ($MN)
  • Table 108 South America Acute Repetitive Seizures Market Outlook, By Drug Type (2021-2030) ($MN)
  • Table 109 South America Acute Repetitive Seizures Market Outlook, By Benzodiazepines (2021-2030) ($MN)
  • Table 110 South America Acute Repetitive Seizures Market Outlook, By Barbiturates (2021-2030) ($MN)
  • Table 111 South America Acute Repetitive Seizures Market Outlook, By Antiepileptic Drugs (AEDs) (2021-2030) ($MN)
  • Table 112 South America Acute Repetitive Seizures Market Outlook, By Other Drug Types (2021-2030) ($MN)
  • Table 113 South America Acute Repetitive Seizures Market Outlook, By Route of Administration (2021-2030) ($MN)
  • Table 114 South America Acute Repetitive Seizures Market Outlook, By Intranasal Formulations (2021-2030) ($MN)
  • Table 115 South America Acute Repetitive Seizures Market Outlook, By Oral (2021-2030) ($MN)
  • Table 116 South America Acute Repetitive Seizures Market Outlook, By Intravenous (2021-2030) ($MN)
  • Table 117 South America Acute Repetitive Seizures Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 118 South America Acute Repetitive Seizures Market Outlook, By Specialty Clinics (2021-2030) ($MN)
  • Table 119 South America Acute Repetitive Seizures Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
  • Table 120 South America Acute Repetitive Seizures Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 121 South America Acute Repetitive Seizures Market Outlook, By Online Pharmacies (2021-2030) ($MN)
  • Table 122 South America Acute Repetitive Seizures Market Outlook, By End User (2021-2030) ($MN)
  • Table 123 South America Acute Repetitive Seizures Market Outlook, By Home Care Settings (2021-2030) ($MN)
  • Table 124 South America Acute Repetitive Seizures Market Outlook, By Clinics (2021-2030) ($MN)
  • Table 125 South America Acute Repetitive Seizures Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 126 Middle East & Africa Acute Repetitive Seizures Market Outlook, By Country (2021-2030) ($MN)
  • Table 127 Middle East & Africa Acute Repetitive Seizures Market Outlook, By Product (2021-2030) ($MN)
  • Table 128 Middle East & Africa Acute Repetitive Seizures Market Outlook, By Diastat Rectal Gel (2021-2030) ($MN)
  • Table 129 Middle East & Africa Acute Repetitive Seizures Market Outlook, By AZ-002 (2021-2030) ($MN)
  • Table 130 Middle East & Africa Acute Repetitive Seizures Market Outlook, By NRL-1 (2021-2030) ($MN)
  • Table 131 Middle East & Africa Acute Repetitive Seizures Market Outlook, By USL-261 (2021-2030) ($MN)
  • Table 132 Middle East & Africa Acute Repetitive Seizures Market Outlook, By Other Products (2021-2030) ($MN)
  • Table 133 Middle East & Africa Acute Repetitive Seizures Market Outlook, By Drug Type (2021-2030) ($MN)
  • Table 134 Middle East & Africa Acute Repetitive Seizures Market Outlook, By Benzodiazepines (2021-2030) ($MN)
  • Table 135 Middle East & Africa Acute Repetitive Seizures Market Outlook, By Barbiturates (2021-2030) ($MN)
  • Table 136 Middle East & Africa Acute Repetitive Seizures Market Outlook, By Antiepileptic Drugs (AEDs) (2021-2030) ($MN)
  • Table 137 Middle East & Africa Acute Repetitive Seizures Market Outlook, By Other Drug Types (2021-2030) ($MN)
  • Table 138 Middle East & Africa Acute Repetitive Seizures Market Outlook, By Route of Administration (2021-2030) ($MN)
  • Table 139 Middle East & Africa Acute Repetitive Seizures Market Outlook, By Intranasal Formulations (2021-2030) ($MN)
  • Table 140 Middle East & Africa Acute Repetitive Seizures Market Outlook, By Oral (2021-2030) ($MN)
  • Table 141 Middle East & Africa Acute Repetitive Seizures Market Outlook, By Intravenous (2021-2030) ($MN)
  • Table 142 Middle East & Africa Acute Repetitive Seizures Market Outlook, By Distribution Channel (2021-2030) ($MN)
  • Table 143 Middle East & Africa Acute Repetitive Seizures Market Outlook, By Specialty Clinics (2021-2030) ($MN)
  • Table 144 Middle East & Africa Acute Repetitive Seizures Market Outlook, By Retail Pharmacies (2021-2030) ($MN)
  • Table 145 Middle East & Africa Acute Repetitive Seizures Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 146 Middle East & Africa Acute Repetitive Seizures Market Outlook, By Online Pharmacies (2021-2030) ($MN)
  • Table 147 Middle East & Africa Acute Repetitive Seizures Market Outlook, By End User (2021-2030) ($MN)
  • Table 148 Middle East & Africa Acute Repetitive Seizures Market Outlook, By Home Care Settings (2021-2030) ($MN)
  • Table 149 Middle East & Africa Acute Repetitive Seizures Market Outlook, By Clinics (2021-2030) ($MN)
  • Table 150 Middle East & Africa Acute Repetitive Seizures Market Outlook, By Other End Users (2021-2030) ($MN)